C[hitin]{.smallcaps} is a structural polymer present in most fungal cell walls. Although its amount varies from 1--30% of the cell wall, it has been shown to be indispensable for the maintenance of the fungal cell (reviewed in [@B9]). In *Saccharomyces cerevisiae*, chitin accounts for only 3% of the cell wall mass. However, some evidence indicates that *S. cerevisiae* cannot survive without chitin ([@B2]; [@B48]). *S. cerevisiae* contains three different chitin synthases (CSs)^1^ responsible for the synthesis of this polymer: CSI acts as a repair enzyme at the time of cytokinesis ([@B7], [@B8]); CSII makes the chitin disk of the primary septum that separates mother and daughter cells ([@B47]; [@B48]); and CSIII makes 90--95% of the cellular chitin, including the chitin synthesized during mating and sporulation ([@B38]; [@B52]; [@B34]). Each CS contains at least one catalytic subunit encoded respectively by *CHS1*, *CHS2*, and *CHS3* gene products (reviewed in [@B4]; [@B9]). These genes show significant similarity, but the differences among them should account for the different kinetics and regulatory requirements of each CS ([@B10]).

The fact that each CS has a different cellular function suggests that the activity of each enzyme must be spatially and temporally regulated. In the case of CSI and CSII, it has been proposed that these would be regulated at the transcriptional ([@B34]) and posttranslational ([@B11]; [@B51]) levels, the latter mechanism achieved through proteolytic processing (reviewed in [@B9]). By contrast, CSIII is not proteolytically regulated and transcriptional regulation of *CHS3*, although it does exist ([@B34]), does not control CSIII activity ([@B11]; [@B14]; [@B15]). In addition to *CHS3*, three other genes, *CHS4*, *CHS5*, and *CHS6*, have been shown to be required for CSIII activity (reviewed in [@B4]). Chs4p has a dual function: it is a direct activator of CSIII activity ([@B50]) and at the same time is responsible for anchoring, through Bni4p, of Chs3p to the septin ring ([@B16]). Chs5p is involved in the polarized transport of Chs3p in specialized vesicles ([@B45]). However, its function is not restricted to Chs3p transport, since it is also involved in the transport of other proteins during mating ([@B46]). Chs6p is required for Chs3p transport in a later step than Chs5p ([@B54]). It also has been shown that Chs3p is subject to endosomal internalization ([@B53]), although the biological meaning of this process is not known. It therefore seems clear that the function of CSIII mainly depends on proper Chs3p transport and localization.

In addition to temporally and spatially regulated chitin synthesis during vegetative growth, there are several circumstances in the life cycle of *S*. *cerevisiae* where chitin synthesis is altered. Chitin synthesis is significantly increased during mating and Calcofluor treatment and in both instances this increase depends on CSIII activity ([@B37],b). During sporulation, CSIII is required to make chitin the precursor of chitosan, a component of the outermost layer of the ascospore wall ([@B34]). However, it is not yet known if chitin/chitosan synthesis is increased during this process. Despite all these findings, there is still no clear picture of how *CHS* genes can regulate chitin synthesis in vivo, and to date only Chs4p can be envisaged as a direct regulator of CSIII activity.

This paper addresses *CHS7*, a new *S. cerevisiae* gene required for CSIII activity. *CHS7* is involved in the regulation of CSIII activity by controlling Chs3p export from the ER. The significance of this specific control mechanism is discussed within the framework of the hierarchy of proteins involved in the control of CSIII activity.

Materials and Methods {#MaterialsMethods}
=====================

Strains, Growth Conditions, and Genetic Methods
-----------------------------------------------

Yeast strains used in this study are listed in Table [I](#TI){ref-type="table"}. *S*. *cerevisiae* strains were grown in YEPD (1% Bacto yeast extract, 2% peptone, 2% glucose) or SD medium (2% glucose, 0.7% Difco yeast nitrogen base without amino acids, 0.07% amino acids solid mix). Growth supplements were added to SD medium when required. *Escherichia coli* was grown in LB medium (1% bactotriptone, 0.5% bacto yeast extract, 1% NaCl) supplemented with 100 μg/ml ampicillin. Standard methods were used for DNA manipulations ([@B43]) and yeast genetics ([@B40]).

Calcofluor resistance was tested by a plate assay ([@B52]) in SD medium buffered with 50 mM potassium hydrogen phthalate, pH 6.1, and supplemented with different Calcofluor concentrations (50-- 1,000 μg/ml; Bayer Industrial Corporation). Calcofluor staining was observed after growing cells in the presence of 75 μg/ml Calcofluor for 2 h at 30°C.

Construction of Plasmids and Strains
------------------------------------

Gene replacement was performed basically as described by [@B41]. The Δ*chs7-1* disruption was constructed by replacing the 1.2-kb NdeI--NdeI fragment containing the *CHS7* coding region (from nucleotide +24--297, downstream from the stop codon) with the *HIS3* gene, thus creating pTM10. The NdeI downstream site is still 724 bp ahead of the next ATG, therefore this deletion should not affect the YHR143 open reading frame (ORF). Strains W303-1A and Y1306 were transformed with a linear 3.5-kb EcoRV--EcoRV fragment from pTM10, containing the *chs7*::*HIS3* gene, giving rise to strains JAY6 and JAY27. The Δ*chs7-2* disruption was constructed by replacement of the 1.2-kb NdeI--NdeI fragment with the *HIS2* gene, affording pTM100. By digestion of pTM100 with SacI, a 4.1-kb fragment containing the *chs7*::*HIS2* gene was used to transform strains HVY374 and HVY376, creating strains JAY25 and JAY26. The Δ*chs6-1* disruption was constructed using a pGEM-*CHS6* plasmid, in which the 1.6-kb BalI--EcoRI internal fragment of *CHS6* was replaced with the *URA3* gene, thus creating pTM12. By digestion of pTM12 with SalI--SphI, a 3.0-kb fragment containing the *chs6*::*URA3* gene was used to transform strain Y1306, obtaining JAY28. Correct replacement of the *CHS7* and *CHS6* loci was determined by PCR analysis and tests of Calcofluor resistance. To construct a fusion gene encoding the full-length Chs7p fused to the green fluorescent protein (GFP; [@B31]), a NotI site was created by directed mutagenesis at the end of the *CHS7* coding region to give pTM14. A 0.7-kb NotI--NotI fragment from pTM13 containing the GFP-encoding sequence ([@B18]) was ligated into NotI-digested pTM14, thus creating pTM15 (pRS316::*CHS7-GFP*). *CHS7*::*3XHA* construction (pTM16) was achieved by inserting a 115-bp NotI--NotI DNA fragment containing three copies of the hemagglutinin epitope (HA) at the same NotI site of pTM14. The functionality of the hybrid proteins was determined by complementation of the phenotypes associated with Δ*chs7*. For intracellular localization of Sec63p, 15Daub cells were transformed with plasmid pRS315::*SEC63-MYC*, kindly provided by R. Schekman (University of California, Berkeley, CA; [@B30]).

Multicopy plasmids pRS423::*CHS3* or pRS423::*CHS3-3XHA* were obtained by inserting the EcoRI--SalI fragment of pHV7 that contains either *CHS3* or *CHS3-3XHA* genes into pRS423 ([@B15]). pRS425:: *CHS4* was done by cloning the *CHS4* gene as a BamHI fragment into pRS425 ([@B50]). Similarly, for construction of pRS426::*CHS7*, *CHS7* gene was cloned as a EcoRV--StuI fragment (pTM11; this work) into pRS426. Plasmids pRS423, pRS425, and pRS426 have been previously described ([@B13]).

Chitin and Chitin Synthase Activity Determinations
--------------------------------------------------

Chitin measurements were performed as described ([@B5]) using chitinase from *Serratia marcescens* (Sigma Chemical Co.). GlcNAc release was determined colorimetrically by the method of [@B35]. Total amounts of chitin are expressed as nanomoles of GlcNAc liberated per 100 mg of cells. For CS activity assays, total cell membranes were prepared from 250 ml of exponentially growing cells (2 × 10^7^ cells/ml) as described by [@B52]. CS activity was measured essentially as described in [@B10]: CSI activity was assayed in 50 mM Tris-HCl, pH 6.5, and 5 mM magnesium acetate; CSII activity was assayed in 50 mM Tris-HCl, pH 8.0, and 5 mM cobalt acetate; and CSIII was assayed in 50 mM Tris-HCl, pH 8.0, with 5 mM cobalt acetate and nickel acetate. For the proteolytic activation step, 2 μl of trypsin (1--3 mg/ml) was added to the reaction medium and proteolysis activation was stopped after 15 min of incubation by adding 2 μl of soybean trypsin inhibitor solution. 1.1 mM UDP\[^14^C\]GlcNAc (Nycomed Amersham; 400 cpm/nmol) was used as substrate for the reaction. Newly synthesized chitin was determined by measuring the radioactivity incorporated into the insoluble material after the addition of 10% trichloroacetic acid and filtration through glass fiber filters (Whatman Inc.; [@B10]). Specific activity is expressed as nanomoles of GlcNAc incorporated per hour per milligram of protein.

Direct and Indirect Immunofluorescence
--------------------------------------

Localization of Chs7p-GFP was observed in exponentially growing cells containing pTM15. After mounting, images were captured with a Zeiss laser-confocal microscope (LSM 510) with a 63× objective and processed with Adobe Photoshop software. Localization of Chs3p-3XHA by indirect immunofluorescence was carried out as described in [@B1] with slight modifications. Spheroplasts were obtained by treatment with 5 μg/ml Zymolyase 100T (Seikagaku) for 30--45 min at 30°C in PEMS (100 mM Pipes, 1 mM EGTA, 1 mM MgSO~4~, 1.2 M sorbitol, pH 6.9) buffer. Mouse HA.11 anti-HA mAb (Berkeley Antibody Co.) was used at a 1:100 dilution for 16 h at 4°C. Cy3-conjugated anti-mouse secondary antibody (Sigma Chemical Co.) was used at a 1:300 dilution for 45 min at 25°C. After mounting, images were captured with a Zeiss laser-confocal microscope (LSM 510) with a 63× objective. For these experiments, an epitope-tagged version of Chs3p in cells whose chromosomal locus had been replaced with *CHS3-3XHA* was used (Strain Y1306; [@B45]). All strains used for immunofluorescence were derived from Y1306. Sec63p-Myc was immunolocalized with a similar protocol, but using supernatants of 9E10 hybridome at 1:100 dilution as primary antibodies ([@B17]).

Northern Blot Analysis
----------------------

For Northern blot analysis, total RNA was prepared as described by [@B43] from cells grown under different conditions. 12.5 μg of total RNA was loaded per lane and after electrophoresis, transferred to Hybond membranes (Nycomed Amersham). Hybridization was carried out as described ([@B43]) using a 1.2-kb NdeI--NdeI fragment from *CHS7* as a probe. For quantitative analysis, Northern blots were exposed to PhosphorImager screens (BASS 1500; FujiFilm). α-Factor treatment for Northern blot experiments was carried out in exponentially growing cells using YEPD medium supplemented with 5 μM α-factor ([@B11]).

Subcellular Fractionation Experiments
-------------------------------------

Cell lysates were prepared (as described in [@B45]) from a JAY25 strain transformed with pRS315::*SEC63-MYC* and pRS316:: *CHS7-3XHA* plasmids. In brief, exponentially growing cells in SD medium (1.5 g wet wt), were resuspended in 5 ml of 17% sucrose (wt/vol) in 50 mM Tris-HCl, pH 7.5, and 1 mM EDTA containing the protease inhibitor cocktail (1 mM phenylmethanesulfonil fluoride and 1 mg/ml each of leupeptin, pepstatin, and aprotinin), and broken by vortexing with glass beads. Lysated cells were centrifuged at 1,500 *g* for 10 min. The cleared supernatant was layered on top of 33 ml of a linear sucrose gradient (10-- 65% wt/vol) in 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, and centrifuged in a SW28 rotor at 25,000 rpm for 20 h at 4°C. 1.25 ml fractions were collected from the bottom using a peristaltic pump. Equal volumes of each fraction were examined for their content of Pma1p, Kre2p, Sec63p-MYC, and Chs7p-HA, determined by SDS-PAGE and immunoblot with their respective antibodies. Rabbit polyclonal antibodies (1:30,000 dilution; kindly provided by Dr. R. Serrano, Universidad de Valencia, Valencia, Spain) were used to detect Pma1p, a typical plasmatic membrane marker. Kre2p, a medial-Golgi compartment protein ([@B29]), was detected using polyclonal antibodies (1:1,000 dilution) kindly supplied by H. Bussey (McGill University, Montreal, Qúebec, Canada). Sec63-MYC, an ER marker, was detected using monoclonal anti-MYC antibodies (supernatants of 9E10 hybridome, 1:5,000 dilution). Mouse HA.11 anti-HA mAb (Berkeley Antibody Co.; 1:2,000 dilution) was used to detect Chs7p-HA. In all cases, Western blots were developed using ECL (Nycomed Amersham).

Western Blot Analysis of Chs3p
------------------------------

Chs3p-3XHA expression levels were determined in total cellular extracts by Western blot analysis as described in [@B15]. Blotted proteins were incubated with mouse HA.11 anti-HA antibody (Berkeley Antibody Co.; 1:2,000 dilution) and developed using ECL (Nycomed Amersham).

Endoglycosidase H (EndoH) treatment was carried out on Chs3p-3XHA after immunoprecipitation under denaturing conditions as described by [@B15]. The immunoprecipitated complex was subjected to Western blot analysis.

Other Methods
-------------

Protein was measured by the method of [@B28]. Yeast strains were mated quantitatively as described in [@B46]. The frequency of diploid formation was estimated as the number of diploids formed out of the total number of cells. Exoglucanase activity was assayed as described by San Segundo et al. (1993); the method is based on the release of reducing sugar groups from laminarin, which were quantified by the method of [@B49] and [@B33]. The α-factor secretion assay was developed as described in [@B32].

Results {#Results}
=======

Isolation of CHS7
-----------------

A new screening for *S. cerevisiae* mutants resistant to Calcofluor was carried out to identify new genes involved in chitin synthesis. Ethyl methanesulfonate-mutagenized JAY1 cells (∼20% of survival) were plated in YEPD media supplemented with 1 mg/ml Calcofluor exactly as described in [@B38]. After 4 d of incubation, 53 bona fide independent clones which were able to grow were selected (mutation frequency 1.1 × 10^−5^). These mutants were back-crossed with previously known Calcofluor resistant and chitin-deficient mutants (*chs3*, *chs4*, and *chs5*). Diploid analysis indicated that most mutants belonged to *chs3* (83%), *chs4* (5.7%), or *chs5* (5.7%) complementation groups. Only three of them, *cwr6*, *cwr12*, and *crw19* (Calcofluor white resistant), defined new complementation groups. Further genetic testing indicated that mutants *cwr12* and *cwr19* belonged to the same group. A preliminary characterization of these mutants indicated that all showed defects in chitin synthesis.

The genes affected in *cwr12* and *cwr6* mutants were cloned by complementation of the Calcofluor resistant phenotype after transformation with a centromeric library ([@B39]). Complementation was confirmed to be dependent on the presence of plasmid and complementing plasmids were isolated in *E*. *coli* for further work. Originally isolated plasmids were subjected to endonuclease restriction mapping and the results obtained indicated that the plasmid complementing *cwr12* contained the previously described *CHS6/CSD3* gene ([@B3]). Therefore, its study was discontinued. The DNA fragment that complemented the *cwr6* mutant contains several ORFs (Fig. [1](#F1){ref-type="fig"} A). Subcloning experiments indicated that the minimum fragment able to complement was the StuI--EcoRV fragment included in pTM11. With these results, we were able to obtain a preliminary identification of YHR0142w as the gene that complements *cwr6* mutation. Due to the defect in CS observed in *cwr6* mutant, we named this gene *CHS7* following accepted nomenclature ([@B6]).

*CHS7* encodes a protein of 316 amino acids that contains six or seven putative transmembrane domains (Fig. [1](#F1){ref-type="fig"}, B and C). It has no significant homology with any known protein, although the search programs showed limited homologies with other transmembrane regions.

Characterization of chs7 Mutants
--------------------------------

We made several *chs7* null mutants by replacing the *CHS7* ORF by different auxotrophic markers (Materials and Methods). Table [II](#TII){ref-type="table"} shows some of the characteristic phenotypes associated with this mutation. *chs7* null mutants had only 13.6% of the wild-type chitin, a defect that was associated with a comparable decrease in CSIII activity. Due to this defect in chitin synthesis, *chs7* cells were resistant to 1 mg/ml Calcofluor and they did not show enlarged septa after Calcofluor treatment. In addition, Δ*chs7/*Δ*chs7* diploids showed compact ascospores, a defect associated with the absence of the chitosan layer ([@B34]). *chs7* mutations also reduced their mating efficiency to a level similar to that of *chs3* mutants (Table [II](#TII){ref-type="table"}). It should be noted that the original *cwr6* mutants showed similar, but less pronounced phenotypes. As expected, wild-type *CHS7* (YHR0142w) in a centromeric plasmid complemented the phenotypes observed in the null (Table [II](#TII){ref-type="table"}, last column) or point (not shown) *chs7* mutants. Once we had constructed null mutants, we confirmed the allelism between YHR142w and *CHS7* genetically. Diploid strain *yhr142*::*HIS3*/*cwr6* was resistant to Calcofluor and analysis of 18 tetrads in this cross showed a Calcofluor resistance segregation of 4:0. Therefore, *CHS7* and YHR142w must be the same gene.

Analysis of CHS7 Expression
---------------------------

To analyze *CHS7* expression levels, we determined *CHS7* mRNA levels in cells harvested after growth under different conditions. *CHS7* was detected in all conditions (Fig. [2](#F2){ref-type="fig"}) as a single band of ∼1.1 kbp, in clear agreement with sequence data. Therefore, *CHS7* is expressed constitutively. However, as shown in Fig. [2](#F2){ref-type="fig"} A, α-factor treatment (mimicking the mating process) increased *CHS7* expression 3.5 times after only 15 min; shortly after, vegetative levels were resumed. Calcofluor treatment also increased *CHS7* expression twofold (Fig. [2](#F2){ref-type="fig"} A, right). Despite its constitutive expression during vegetative growth, *CHS7* mRNA levels were strongly increased during sporulation, reaching a maximum (∼24-fold more) after 10 h of sporulation induction. Thereafter, *CHS7* mRNA levels slowly decreased. The typical expression pattern observed resembled that of a middle sporulation gene ([@B23]; [@B20]). These results allowed us to conclude that the expression of *CHS7* is transcriptionally regulated. In addition, *CHS7* transcription increased under all growth conditions in which chitin synthesis was increased.

Chs7p Is a Membrane Protein Localized in the ER
-----------------------------------------------

Chs7p was tagged at the COOH terminus either with the 3XHA epitope or GFP (Materials and Methods) to determine the subcellular localization of Chs7p. Chimeric proteins Chs7p-3XHA or Chs7p-GFP complemented the Calcofluor resistance phenotype of *chs7* null mutant (JAY6 strain). In addition, the chimeric proteins restored wild-type levels of chitin synthesis in this strain, as determined by chitin staining with Calcofluor ([@B15]). It can be concluded that Chs7p-3XHA and Chs7p-GFP are fully functional. Western blot analysis indicated that Chs7p-3XHA runs as a 35-kD protein that is localized in the particulate fraction (data not shown). Molecular size and subcellular localization are in clear agreement with sequence predictions. Logarithmically growing cells expressing Chs7p-GFP from its own promoter showed the fluorescent staining depicted in Fig. [3](#F3){ref-type="fig"} A. Chs7p-GFP was uniformly localized in the nuclear periphery and in discrete patches associated with the cytoplasmic membrane. This pattern coincides with that of Sec63p-Myc (Fig. [3](#F3){ref-type="fig"} B), a typical ER marker ([@B42]). The vacuolar staining observed seems to be an artifact because it does not appear in all the cells and it does not show the typical green color of GFP (data not shown). A similar distribution in the ER was observed by indirect immunofluorescence in cells expressing Chs7p-3XHA (data not shown). No polarized distribution of Chs7p was observed in either case. To confirm the immunofluorescence results a subcellular fractionation experiment was carried out. Total cellular extract were loaded into the top of a linear sucrose density gradient and after centrifugation, Pma1p, Sec63p-MYC, Kre2p, and Chs7p-3XHA distribution was analyzed by Western blot as described in Materials and Methods. Fig. [3](#F3){ref-type="fig"} C shows that membrane protein Pma1p is localized at the bottom of the gradient, mainly between fraction 1 to 4. Sec63p is localized from fractions 5 to 17, with a significant peak between the 11 to 15 fractions. Chs7p distribution is quite similar with that of Sec63, also showing maximum accumulation between 11 to 15 fractions. Golgi compartment distribution, marked by Kre2p ([@B29]), is displaced to lighter fractions. Therefore, it can be concluded that Chs7p is an ER membrane protein.

Chs7p Is Required for Chs3p Export from the ER
----------------------------------------------

Functional CSIII activity depends on the appropriate synthesis and transport of Chs3p, its catalytic subunit. Chs7p does not seem involved in the synthesis of Chs3p, since Chs3p levels in Δ*chs7* mutants are similar to those observed in wild-type (Fig. [4](#F4){ref-type="fig"} A). Therefore, Chs7p could be involved in the transport of Chs3p, a process that is mediated by Chs4p, Chs5p, and Chs6p. Following a strategy similar to that used in the characterization of these genes, we localized an HA-tagged version of Chs3p ([@B45]) in wild-type and *chs7*-null mutants. As previously reported ([@B14]; [@B45]), Chs3p-3XHA localized in the base of the emerging bud in wild-type strains (Fig. [4](#F4){ref-type="fig"} C, a). However, in Δ*chs7* mutants all the Chs3p-3XHA remained in the ER, showing a perinuclear localization with partial association with the plasma membrane (Fig. [4](#F4){ref-type="fig"} C, b, compare to Fig. [3](#F3){ref-type="fig"} A). No polarized distribution of Chs3p-3XHA was observed in Δ*chs7* mutants. Higher magnification (Fig. [4](#F4){ref-type="fig"} C, c) indicated that the perinuclear staining was punctuated, suggesting possible Chs3p aggregation. In addition, it is important to notice that although retained in the ER, Chs3p-3XHA is correctly core-glycosylated in *chs7* mutants (Fig. [4](#F4){ref-type="fig"} B). Therefore, it can be concluded that Chs7p is required for Chs3p export from the ER and Chs7p must be the initial step in the hierarchy of proteins required for CSIII activity. To confirm this hypothesis, we analyzed the localization of Chs3p-3XHA in Δ*chs4* Δ*chs7*, Δ*chs5* Δ*chs7*, or Δ*chs6* Δ*chs7* double mutants (Fig. [5](#F5){ref-type="fig"}, B, D, and F). In all cases, Chs3p was retained in the ER and did not show the localization described for Δ*chs4*, Δ*chs5*, or Δ*chs6* single mutants. As previously reported ([@B16]), the distribution of Chs3p in Δ*chs4* mutant was polarized (Fig. [5](#F5){ref-type="fig"} A). However, it was not as densely packed at the base of the bud as in the wild-type (Fig. [4](#F4){ref-type="fig"} C, a). In Δ*chs5* and Δ*chs6* mutants, Chs3p was localized in internal vesicles (Fig. [5](#F5){ref-type="fig"}, C and E) without polarized distribution ([@B45]; [@B54]). From these results, we conclude that the *chs7* mutation is epistatic to the *chs* mutations and that Chs7p is necessary for Chs3p export from the ER.

Chs7p Is Not Required for the Transport of other Proteins
---------------------------------------------------------

Chs7p could play a general role in secretion or protein sorting rather than being specific for chitin synthesis. To test this hypothesis, we analyzed the behavior of several secreted or sorted proteins in Δ*chs7* mutants. α-factor and exo-β(1-3)glucanase are two extracellular *S. cerevisiae* proteins that follow the normal secretion route. Fig. [6](#F6){ref-type="fig"} shows that the expression levels of these two proteins are unaffected in Δ*chs7* mutants. Similarly, CSI and CSII, the other two CS activities present in *S. cerevisiae*, showed wild-type levels in Δ*chs7* mutants. Apparently, Chs7p is not required for secretion or sorting of other cellular proteins.

In addition to the regular secretion mechanism, *S. cerevisiae* contains several other mechanisms involved in the specific assembly and transport of certain proteins. Sorting of vacuolar ATPase (v-ATPase) or several amino acid permeases to cytoplasmic membrane has been shown to depend on specific mechanisms of export from the ER (reviewed in [@B22]), raising the possibility of the involvement of Chs7p is such processes. However, *chs7* null mutants grew in glycerol and did not show synthetic lethality with other amino acid auxotrophies, clear indications that v-ATPase and amino acid permeases function properly in Δ*chs7* mutants.

Chs7p Is a Limiting Factor in the Constitution of Functional CSIII Activity
---------------------------------------------------------------------------

So far we have shown that Chs7p is required for Chs3p export. However, from Fig. [2](#F2){ref-type="fig"} it is also apparent that *CHS7* expression increases when more chitin is synthesized. These observations suggest that the level of expression of *CHS7* could be involved in the control of CSIII activity. If so, this would explain why overexpression of *CHS3* does not increase CSIII levels. To confirm this possibility, we measured CSIII activity in strains overexpressing *CHS* genes in different combinations. Overexpression of *CHS3* ([@B15]) or *CHS7* (Fig. [7](#F7){ref-type="fig"}) alone had no significant effect on CSIII. As previously reported ([@B50]), overexpression of *CHS4* increased CSIII activity and reduced its trypsin dependence. Joint overexpression of *CHS4* and *CHS3* or *CHS4* and *CHS7* did not alter the effect of *CHS4* on CSIII (Fig. [7](#F7){ref-type="fig"}). Cooverexpression of *CHS3* and *CHS7* increased total CSIII almost four times. However, basal activity was only increased 1.3 times and, as a consequence, the activation factor by trypsin treatment was almost five times, in comparison with 1.6--2 times, for the controls. Joint overexpression of *CHS4*, *CHS3*, and *CHS7* did not further increase total CSIII activity. However, basal activity was increased more than twofold. Therefore, activation by trypsin treatment was reduced to 2.5 in this case. Taken together, these results indicate that the amounts of Chs7p and Chs3p act as limiting factors to total CSIII activity. In addition, Chs4p levels are also limiting in the reconstitution of an in vitro fully active CSIII. Overexpression of *CHS3*, *CHS4*, and *CHS7* genes also induced a modest, but significant, increase in chitin synthesis in vivo because a strain overexpressing these three genes contained ∼68 ± 11% more chitin than the corresponding wild-type. This increase in chitin synthesis was not observed if only *CHS3* and *CHS7* were overexpressed (not shown).

These results clearly suggest that the amount of Chs7p is a limiting factor in vivo for CSIII activity and therefore, could be the reason for the absence of an increase in CSIII activity after *CHS3* overexpression. In fact, immunostaining of cells overexpressing *CHS3-3XHA* alone revealed a severe retention of Chs3p in the ER even in the presence of normal amounts of Chs7p (Fig. [8](#F8){ref-type="fig"} A). Cooverexpression of *CHS3* with *CHS7* dramatically reduced Chs3p accumulation in the ER (Fig. [8](#F8){ref-type="fig"} B) and only residual staining was observed at ER level. In this case, Chs3p was mainly localized in discrete patches in the cytoplasm, which in some cells showed a polarized distribution (Fig. [8](#F8){ref-type="fig"} B, arrows). This distribution resembled an intermediate stage between Δ*chs6*, Δ*chs5*, and Δ*chs4* mutants (Fig. [5](#F5){ref-type="fig"}, A, C, and E). In sum, Chs3p excess is not retained in the ER in the presence of high levels of Chs7p and hence, higher levels of functional CSIII activity are achieved.

Discussion {#Discussion}
==========

Chitin is a minor, but essential polymer in the *S. cerevisiae* cell wall. Despite its low abundance, three different CS activities have been described in this yeast ([@B9]). From a quantitative point of view, CSIII activity is the most important, since it is involved in the synthesis of 90--95% of cell wall chitin during vegetative growth ([@B38]; [@B52]; [@B3]). In addition, it is required for the synthesis of new chitin that takes place during the mating and sporulation processes ([@B38]; [@B34]).

Recently, it has been shown that the transcriptional regulation of *CHS3*, the gene that encodes the catalytic subunit of CSIII, is not the control mechanism for CSIII activity ([@B11]; [@B14]; [@B15]). Therefore, the identification of genes involved in the control of CSIII and chitin synthesis gains interest. Three proteins, Chs4p, Chs5p, and Chs6p, have been identified, so far, as factors involved in the control of CSIII activity. This report deals with the isolation of a new gene, *CHS7*, also involved in the control of CSIII activity. *CHS7* was isolated by complementation of a mutant resistant to Calcofluor, showing that this strategy still has potential, although most (83%) of the mutants isolated belong to the *chs3* complementation group.

Δ*chs7* mutants have reduced levels of CSIII activity and chitin in their cell walls (Table [II](#TII){ref-type="table"}). This defect is comparable to that observed in *chs3* null mutants ([@B15]) and stronger than that detected in *chs4* ([@B50]), *chs5* ([@B46]), or *chs6* mutants ([@B4]), underscoring the relevance of this gene in the control of CSIII activity. *CHS7* encodes a small protein with six or seven putative transmembrane domains ([@B26]). Repeated database searches using different algorithms did not reveal any protein with significant homology to this protein. Some Chs7p regions with similarity to other integral membrane proteins probably reflect the hydrophobicity of the membrane-spanning domains rather than protein conservation. Chs7p colocalized with Chs3p in a crude particulate cell fraction and we therefore expected to find colocalization of Chs3p and Chs7p in the plasma membrane. However, Chs7p was localized exclusively in the ER (Fig. [3](#F3){ref-type="fig"}), showing the typical localization of other ER proteins such as Sec63p ([@B42]; Fig. [3](#F3){ref-type="fig"} B). This localization does not seem to be an artifact of the chimeric Chs7p-GFP because similar results were obtained with Chs7p-3XHA either in immunofluorescence (data not shown) or in subcellular fractionation (Fig. [3](#F3){ref-type="fig"} C) experiments.

A functional explanation to account for this localization, unique among Chs proteins, became apparent when we observed that Chs3p accumulates at the ER in the absence of Chs7p (Fig. [4](#F4){ref-type="fig"} C, b). However, the Chs3p protein accumulated in the *chs7* mutant is correctly core-glycosylated (Fig. [4](#F4){ref-type="fig"} B), a clear indication that Chs3p is translocated and correctly localized in the ER compartment in this mutant. Therefore, Chs7p should be required for Chs3p export from the ER. Moreover, the *chs7* mutation is epistatic over other *chs* mutations, suggesting that Chs7p is the initial element in the hierarchy of proteins involved in CSIII activity. These results explain the stronger defect in CSIII activity observed in Δ*chs7*, as compared with Δ*chs4*, Δ*chs5*, or Δ*chs6* mutants. It should be noted that Chs4p, Chs5p, or Chs6p is not required for Chs3p export from the ER (Fig. [5](#F5){ref-type="fig"}). At this point, all the data points to the specific involvement of Chs7p in the export of Chs3p from the ER. However, the concomitant participation of other *CHS* products in this export cannot be ruled out. Despite this, preliminary evidence indicates that Chs5p and Chs4p are efficiently exported in Δ*chs7* mutants (data not shown) and therefore, their participation is rather unlikely.

To date, there is no clear relationship between the levels of expression of different *CHS* genes and chitin levels, although regulation of chitin synthesis has been observed during the yeast life cycle ([@B37],b; [@B34]). It should especially be stressed that overexpression of *CHS3* several times (∼30) did not increase CSIII activity or chitin levels ([@B15]) and that Chs3p levels remain stable during vegetative growth ([@B11]; [@B14]). Under these circumstances, only Chs4p can be envisaged as a controller of CSIII activity ([@B4]; [@B50]). Might Chs7p also be involved in the control of CSIII? Fig. [2](#F2){ref-type="fig"} shows some results in favor of this hypothesis, since *CHS7* is the only *CHS* gene whose transcription is increased under all conditions in which chitin synthesis is seen to be increased: mating, Calcofluor treatment, and sporulation. The increase in *CHS7* expression during sporulation is especially relevant and its pattern of induction resembles that of a middle-late sporulation gene ([@B20]). The timing of expression places *CHS7* among the sporulation genes involved in spore wall formation ([@B23]; [@B20]). Further and more direct confirmation of this hypothesis was achieved after joint overexpression of *CHS3* and *CHS7* genes. CSIII activity rose dramatically after the overexpression (Fig. [7](#F7){ref-type="fig"}), reaching values several-fold higher than those of the control strain. This increase depends on joint overexpression, suggesting the requirement of a balanced expression of both genes.

Biochemically, we have shown that Chs7p acts as a limiting factor when Chs3p levels are increased, but the reason at an intracellular level for this limitation remains unknown. As shown in Fig. [8](#F8){ref-type="fig"} A, the cells cannot process an excess of Chs3p and therefore, overexpression of *CHS3* leads to Chs3p retention in the ER. However, if *CHS7* is overexpressed in strains with high levels of Chs3p, this protein is released from the ER (Fig. [8](#F8){ref-type="fig"} B). In addition, the localization of Chs3p in this strain resembles that observed in Δ*chs6* ([@B54]) or Δ*chs5* ([@B45]) mutants (bright internal spots) with partial polarization (Fig. [8](#F8){ref-type="fig"} B, arrows), as in *chs4* mutants (Fig. [5](#F5){ref-type="fig"} B; [@B16]). These results indicate that although Chs3p is efficiently exported from the ER, its transport to its physiological site of action is impaired, probably due to some other limiting factors. In this condition, the high amount of active CSIII detected suggests that the limiting factor, if it exists, should appear at the time of or after *CHS6* participation, because mutations in genes that function early on the pathway show severe defects in CSIII activity ([@B4]; [@B46]).

Chitin synthesis increases in *S*. *cerevisiae* during α-factor treatment and this process is associated with the increase in CSIII activity ([@B37]). Recently, it has been shown that during α-factor treatment Chs3p levels increase significantly ([@B15]). However, no Chs3p is localized at the ER ([@B45]). We have shown that the effect of increased Chs3p levels on chitin synthesis depends mainly on correct Chs3p export from the ER. Therefore, the increase in *CHS7* transcription observed during α-factor treatment (Fig. [2](#F2){ref-type="fig"} A) guarantees the export of excess Chs3p and the increase in chitin synthesis required during this process.

Overexpression of *CHS3* and *CHS7* leads to a significant increase in CSIII activity. However, the activity obtained under these conditions was highly zymogenic. When we increased Chs4p levels in the same experiment, the CSIII dependence on trypsin decreased significantly. Therefore, it seems that Chs4p is also a limiting factor for this activity. We cannot be sure if Chs4p function is mediated by proteolytic processing of CSIII, but it does seem clear that in vitro trypsin treatment of CSIII resembles the activation carried out in vivo by Chs4p. Moreover, the strain carrying the triple overexpression also showed a significant increase in cellular chitin levels (68% higher than controls) indicating that these genes not only participate in the control of CSIII, but also in the in vivo control of chitin synthesis. We cannot expect a perfect correlation between CSIII and chitin levels, since there could be as yet undescribed cellular determinants participating in this process. In addition, problems of interference could arise in the replication of three independent plasmids that could mask quantitative interpretation of these data. By contrast, strains overexpressing only *CHS3/CHS7*, although they showed high CSIII activity, did not show any increase in chitin levels. This result is the first experimental evidence that Chs4p is an in vivo regulator of chitin synthesis because until now, the Chs4p function has only been determined in CSIII measurements in vitro ([@B4]; [@B12]; [@B50]).

With this evidence in mind, it can be concluded that the extent of CSIII activity in vivo depends on a delicate balance between the levels of Chs3p, Chs4p, and Chs7p proteins, a balance that ensures the level of chitin synthesis required at each moment of the *S. cerevisiae* life cycle, besides the specific roles of CSI and CSII activities.

At this point, we are still unable to pinpoint the exact role of Chs7p in the export of Chs3p. However, we can compare this system with the assembly of v-ATPase or the transport of amino acid permeases, the two previously reported cases in *S. cerevisiae* that involve specific proteins in their exit from the ER (reviewed in [@B22]). v-ATPase mature complex is assembled in the ER with the help of several proteins, such as Vma12p or Vma22p, which do not leave the ER and therefore do not participate in the active v-ATPase complex ([@B19]). Likewise, Shr3p is required for the release of several amino acid permeases from the ER ([@B27]). If this protein is not present, the amino acid permeases cannot be loaded into COPII vesicles ([@B24], [@B25]). We can exclude the participation of *CHS7* in any of these processes because *chs7* mutants did not show phenotypes associated with the lack of v-ATPase or the amino acid permeases. The role of Chs7p in the export of Chs3p could be similar to that reported in any of these cases. In the absence of Chs7p, the CSIII complex, including Chs3p, is either not assembled or not loaded into secretory vesicles. There is indirect evidence suggesting that Chs7p could have a similar role to Shr3p. First of all, Shr3p and Chs7p, although lacking significant homology, have a very similar secondary structure with several transmembrane domains. This type of secondary structure is typical of resident ER proteins (outfitters) rather than proteins loaded into cargo vesicles (escorts or guides; [@B21]). Chs7p also lacks the protein sequences involved in COPI mediated retrograde transport. In addition, we have been unable to detect Chs7p outside of the ER compartment. However, we cannot exclude that Chs7p is rapidly recycled between the ER and Golgi compartments. The answer to this question will have to await the description of the nature of the secretory vesicles involved in the transport of Chs3p.

The results reported here indicate that *CHS7* is part of a specific mechanism for CS export and its presence in vertebrates is therefore unlikely. This opens a new possibility in the design of an antifungal agent that selectively inhibits chitin synthesis.
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###### 

S. cerevisiae Strains Used in this Study

  Strain        Relevant genotype                                                  Source
  ---------- -- --------------------------------------------------------------- -- -------------------------------------------------------
  X2180-1A      *MAT**a**, SUC2, mal, mel, gal2, CUP1*                             American Type Culture Collection
  JAY1          X2180-1A *ura3*                                                    This study
  W303-1A       *MAT**a** can1-100 ade2-1 his3-11,15 leu2-3,12 trp1-1 ura3-1*      Lab Collection
  JAY6          W303-1A *chs7*::*HIS3*                                             This study
  YPA24         [*MAT*α *ade2 ura3 leu1 cyh2 can1*]{.ul}                           Lab Collection
                *MATa ade2-1 ura3-1 leu2-3 his3-11 can1-100*                       
  15D           *MAT**a** leu2 ade1 his1 trp1*                                     [@B36]
  15Daub        15D Δ*bar1 ura3* Δ*ns*                                             [@B36]
  HVY374        15D *ura3* Δ*ns ADE1*                                              Dr. Valdivieso[\*](#TFI-150){ref-type="table-fn"}
  HVY376        15D*MAT* α *ura3* Δ*ns TRP1*                                       Dr. Valdivieso[\*](#TFI-150){ref-type="table-fn"}
  JAY21         HVY374 *chs3*::*LEU2*                                              This study
  JAY22         HVY376 *chs3*::*LEU2*                                              This study
  JAY25         HVY374 *chs7*::*HIS2*                                              This study
  JAY26         HVY376 *chs7*::*HIS2*                                              This study
  Y604          *MAT**a** ura3-52 lys2-801 ade2-101 trp1-901 his3 Δ200*            Dr. Santos[‡](#TFI-152){ref-type="table-fn"} ([@B45])
  Y1306         Y604 *CHS3*::*3xHA*                                                Dr. Santos[‡](#TFI-152){ref-type="table-fn"} ([@B45])
  JAY27         Y1306 *chs7*::*HIS3*                                               This study
  JAY28         Y1306 *chs6*::*URA3*                                               This study
  JAY29         Y1306 *chs4*::*URA3*                                               This study
  JAY30         Y1306 *chs5*::*ADE2*                                               This study
  JAY31         Y1306 *chs4*::*URA3 chs7::HIS3*                                    This study
  JAY32         Y1306 *chs6*::*URA3chs7::HIS3*                                     This study
  JAY33         Y1306 *chs5*::*ADE2 chs7::HIS3*                                    This study

 Departmento de Microbiología y Genética/Instituto de Microbiología Bioquímica, Consejo Superior de Investigaciones Cientificas/Universidad de Salamanca.  

  Yale University, New Haven, CT.  

![Identification and characteristics of Chs7p. (A) Subcloning strategy used in the identification of YHR142 as complementing gene for the *cwr6* mutants. Complementation was determined by analyzing the reversal of Calcofluor resistance in *cwr6* cells. Useful restriction sites are indicated: E, EcoRI; C, ClaI; V, EcoRV; X, XbaI; St, StuI; B, BamHI; P, PstI; K, KpnI; and S, SalI. (B) Amino acid sequence of Chs7p. Membrane-spanning domains are underlined. (C) Kyte-Doolittle hydrophobicity plot of Chs7p.](JCB9812082.f1){#F1}

###### 

Characteristic Phenotypes of cwr6 (chs7) Mutants

  Phenotype                                                     Strains[\*](#TFII-150){ref-type="table-fn"}                                    
  ---------------------------------------------------------- -- --------------------------------------------- -- ------ -- ------ -- ------ -- -------
  Calcofluor resistance[‡](#TFII-152){ref-type="table-fn"}      −                                                \+        \+        \+        −
  Septa enlargement[§](#TFII-153){ref-type="table-fn"}          \+                                               −         −         −         \+
  Chitin [¶](#TFII-154){ref-type="table-fn"}                    100                                               6.5      21.6      13.6       87.6
  CSIII [¶](#TFII-154){ref-type="table-fn"}                     100                                              15.8      28.2      14.6      103.4
  Mating efficiency [¶](#TFII-154){ref-type="table-fn"}         100                                              69.3      ND        65.3      ND
  Compact ascospores[‖](#TFII-155){ref-type="table-fn"}         No                                               Yes       ND        Yes       ND

 All strains used, except the original *cwr6* mutant, are isogenic derivatives of HVY374 obtained by gene replacement (Table [I](#TI){ref-type="table"}).  

 Growth in buffered minimal media supplemented with 1 mg/ml Calcofluor.  

 Presence (+) or absence (−) of enlarged septa after 2 h of growth in YEPD media supplemented with 75 μg/ml Calcofluor.  

 Numeric values represent the percentage of the values obtained for each strain compared to that of wild-type. Chitin, CSIII, and mating efficiency were determined as described in Materials and Methods.  

 Determined by observation under phase-contrast microscope.  

![Transcription levels of *CHS7*. Northern blots were done with RNAs obtained from cells grown under different conditions and loaded in equivalent amounts. *CHS7* mRNA was detected using the NdeI--NdeI fragment as a probe (Materials and Methods). In all cases, autoradiographic images and quantitative determinations by PhosphorImager (Materials and Methods) are shown. Relative amounts of *CHS7* mRNA are referred to actin levels (not shown) and normalized with respect to the value obtained at the respective control points (left lane of each figure). (A) RNA was obtained from X2180-1A cells incubated for the indicated times on 5 μM α-factor (left) or from cells grown for 2 h in the absence (−) or presence (+) of 50 μg/ml Calcofluor. (B) RNA was obtained from YPA24 diploid strain incubated in sporulation medium for the indicated times.](JCB9812082.f2){#F2}

![Localization of Chs7p. (A) JAY25 cells transformed with pTM15 (pRS316::*CHS7-GFP*) were visualized directly in a Zeiss laser-confocal microscope under appropriate excitation conditions. Note the continuous staining along the nuclear periphery and the patches associated with cytoplasmic membrane. Cells shown on the lower part of the figure are in the process of nuclear division. (B) Indirect immunofluorescence localization of Sec63p-Myc in wild-type (15Daub) cells transformed with pRS315::*SEC63-MYC*. (C) Western blot experiments showing subcellular distribution of several proteins after equilibrium centrifugation in a sucrose gradient. Fractions were collected from the bottom (lower fractions, higher densities). Equal volumes of each fraction were loaded per lane (Materials and Methods).](JCB9812082.f3){#F3}

![Characterization of Chs3p in wild-type and Δ*chs7* mutants. (A) Expression levels of Chs3p-3XHA in wild-type and Δ*chs7* strains. (B) Mobility of Chs3p-3XHA from wild-type and Δ*chs7* before (−) and after (+) EndoH treatment. Chs3p\* indicates mobility of the protein after N-glycosylation removal. Protein extracts (A and B) were prepared from HVY374 (wild-type) and JAY25 (Δ*chs7*) strains transformed with plasmid pHV7-*CHS3*::*3XHA* and detected by Western blot (Materials and Methods). (C) Chs3p-3XHA detected by indirect immunofluorescence with HA.11 antibody. Early logarithmically growing cells were processed as described in Materials and Methods. Strains: a, Y1306 (*CHS3*::*3XHA*); b and c, JAY27 (*CHS3*::*3XHA*, *chs7*::*HIS3*). (a) Polarized Chs3p distribution in wild-type cells. (b and c) Typical ER distribution of Chs3p in Δ*chs7* mutant. Note the irregular distribution (dotted staining) observed after higher magnification in c. Bars, 2 μm.](JCB9812082.f4){#F4}

![Immunolocalization of Chs3p-3XHA in *chs* mutants. All cells are Y1306 (*CHS3*::*3XHA*) with different *chs* mutations. (A) JAY29, *chs4*::*URA3*. (B) JAY31, *chs4*::*URA3 chs7*::*HIS3*. (C) JAY30, *chs5*::*ADE2*. (D) JAY33, *chs5*::*ADE2 chs7*::*HIS3*. (E) JAY28, *chs6*::*URA3*. (F) JAY32, *chs6*::*URA3 chs7*::*HIS3*. (A, C, and E) Polarized distribution of Chs3p at the base of the emerging bud (Fig. [4](#F4){ref-type="fig"} A) is lost in *chs* mutants. Each *chs* mutant shows the typical Chs3p localization as described. (B, D, and F) In Δ*chs7* mutants, Chs3p-3XHA shows ER localization.](JCB9812082.f5){#F5}

![Secretion phenotypes of Δ*chs7* mutants. (A) Production of α-factor measured by the size of the growth inhibition halo. (B) Activities of several enzymatic activities in wild-type and *chs7* null mutants. Activities were determined in HVY374 (WT) and JAY25 (*chs7*::*HIS2*) isogenic strains and expressed as described in Materials and Methods.](JCB9812082.f6){#F6}

![CSIII activity in strains overexpressing *CHS* genes. CSIII activity was determined in cell extracts with (total activity) or without (basal activity) trypsin activation (Materials and Methods). Numbers indicate the ratio between total and basal activity. The results are the average of three independent experiments. Standard deviation bars are shown. On the abscissa, the names of overexpressed *CHS* genes are indicated in each case. Overexpression was achieved by transforming wild-type (15Daub) cells with multicopy plasmids: pRS423::*CHS3*, pRS425:: *CHS4*, or pRS426::*CHS7* (Materials and Methods).](JCB9812082.f7){#F7}

![Immunolocalization of overexpressed Chs3p-3XHA. (A) Characteristic ER staining of strain Y604 transformed with pRS423::*CHS3-3XHA* after immunodetection of Chs3p-3XHA. (B) Chs3p-3XHA localization in Y604 cotransformed with pRS423::*CHS3-3XHA* and pRS426::*CHS7*. Note the dotted staining in most cells, some showing polarized staining (arrows). Some cells also show residual perinuclear staining.](JCB9812082.f8){#F8}
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